
    
      A study to evaluate the role of ombitasvir/paritaprevir/ritonavir and dasabuvir
      coadministered with RBV treatment leading to sustained virologic response 12 weeks
      post-dosing (SVR12) on the changes from baseline in IFN-stimulated gene (ISG) expression in
      peripheral blood mononucleated cells (PBMCs) in HCV GT 1a-infected adult participants.
    
  